263 related articles for article (PubMed ID: 29550382)
1. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.
Brown JR; Hamadani M; Hayslip J; Janssens A; Wagner-Johnston N; Ottmann O; Arnason J; Tilly H; Millenson M; Offner F; Gabrail NY; Ganguly S; Ailawadhi S; Kasar S; Kater AP; Doorduijn JK; Gao L; Lager JJ; Wu B; Egile C; Kersten MJ
Lancet Haematol; 2018 Apr; 5(4):e170-e180. PubMed ID: 29550382
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC
Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803
[TBL] [Abstract][Full Text] [Related]
3. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.
Pagel JM; Soumerai JD; Reddy N; Jagadeesh D; Stathis A; Asch A; Salman H; Kenkre VP; Iasonos A; Llorin-Sangalang J; Li J; Zelenetz AD
Lancet Oncol; 2022 Aug; 23(8):1021-1030. PubMed ID: 35835137
[TBL] [Abstract][Full Text] [Related]
4. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Kater AP; Arslan Ö; Demirkan F; Herishanu Y; Ferhanoglu B; Diaz MG; Leber B; Montillo M; Panayiotidis P; Rossi D; Skarbnik A; Tempescul A; Turgut M; Mellink CH; van der Kevie-Kersemaekers AF; Lanham S; Sale B; Del Rio L; Popovic R; Chyla BJ; Busman T; Komlosi V; Wang X; Sail K; Pena GE; Vizkelety T; Forconi F
Lancet Oncol; 2024 Apr; 25(4):463-473. PubMed ID: 38467131
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
Wang Z; Zhou H; Xu J; Wang J; Niu T
Front Immunol; 2022; 13():1070660. PubMed ID: 36685572
[TBL] [Abstract][Full Text] [Related]
6. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Duell J; Abrisqueta P; Andre M; Gaidano G; Gonzales-Barca E; Jurczak W; Kalakonda N; Liberati AM; Maddocks KJ; Menne T; Nagy Z; Tournilhac O; Kuffer C; Bakuli A; Amin A; Gurbanov K; Salles G
Haematologica; 2024 Feb; 109(2):553-566. PubMed ID: 37646664
[TBL] [Abstract][Full Text] [Related]
7. Symptomatic leptomeningeal carcinomatosis: a rare presentation of chronic lymphocytic leukaemia relapse.
Batayneh O; Lin A; Abu-Jaradeh O; Wu P; Villamar MF; Sharma P
BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35675961
[TBL] [Abstract][Full Text] [Related]
8. Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.
Wang ML; Barrientos JC; Furman RR; Mei M; Barr PM; Choi MY; de Vos S; Kallam A; Patel K; Kipps TJ; Rule S; Flanders K; Jessen KA; Ren H; Riebling PC; Graham P; King L; Thurston AW; Sun M; Schmidt EM; Lannutti BJ; Johnson DM; Miller LL; Spurgeon SE
NEJM Evid; 2022 Jan; 1(1):EVIDoa2100001. PubMed ID: 38319241
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia.
Marchand T; Pastoret C; Damaj G; Lebouvier A; Herbaux C; Moignet A; Pavlosky M; Pavlosky A; Blouet A; Eloit M; Launay V; Lebreton P; Stamatoullas A; Nilsson C; Ochmann M; Prola J; Lamy T
Br J Haematol; 2024 Apr; ():. PubMed ID: 38639192
[TBL] [Abstract][Full Text] [Related]
10. Development of a Conceptual Model of Chronic Lymphocytic Leukemia to Better Understand the Patient Experience.
Eek D; Blowfield M; Krogh C; Chung H; Eyre TA
Patient; 2021 Jan; 14(1):75-87. PubMed ID: 32808103
[TBL] [Abstract][Full Text] [Related]
11. Duvelisib: A comprehensive profile.
Aljohar HI; Al-Abdullah E; Alzoman NZ; Darwish HW; Darwish IA
Profiles Drug Subst Excip Relat Methodol; 2024; 49():19-40. PubMed ID: 38423708
[TBL] [Abstract][Full Text] [Related]
12. Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data.
Marschner N; Knauf W
Oncol Res Treat; 2024 Mar; ():1-11. PubMed ID: 38493778
[TBL] [Abstract][Full Text] [Related]
13. The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival.
Danilov AV; Flinn IW; Davids MS; Gregory B; Bentur O; Sidransky D; Brown JR
Haematologica; 2024 May; ():. PubMed ID: 38813715
[TBL] [Abstract][Full Text] [Related]
14. Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study.
Lamure S; Duléry R; Di Blasi R; Chauchet A; Laureana C; Deau-Fischer B; Drenou B; Soussain C; Rossi C; Noël N; Choquet S; Bologna S; Joly B; Kohn M; Malak S; Fouquet G; Daguindau E; Bernard S; Thiéblemont C; Cartron G; Lacombe K; Besson C
EClinicalMedicine; 2020 Oct; 27():100549. PubMed ID: 33073216
[TBL] [Abstract][Full Text] [Related]
15. Sinonasal Lymphoma Presenting as a Probable Sanctuary Site for Relapsed B Acute Lymphoblastic Leukaemia: A Case Report and Review of the Literature.
Lim WY; Care R; Lau M; Chiruka S; Dawes PJ
Case Rep Hematol; 2015; 2015():697957. PubMed ID: 26697242
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia.
Yang L; Banerji V
Lancet Oncol; 2024 Apr; 25(4):413-414. PubMed ID: 38547887
[No Abstract] [Full Text] [Related]
17. Chronic lymphocytic leukaemia in the elderly.
Han ST; Aftab N
Clin Med (Lond); 2023 Nov; 23(Suppl 6):56-57. PubMed ID: 38182240
[No Abstract] [Full Text] [Related]
18. Mortality trends of chronic lymphocytic leukaemia in the United States with the emergence of targeted therapy.
Tan JY; Yeo YH; Tan MC; Chavez JC; Chisti MM
Br J Haematol; 2024 Mar; 204(3):1114-1117. PubMed ID: 38155366
[No Abstract] [Full Text] [Related]
19. Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia.
Vargova J; Vargova K; Dusilkova N; Kulvait V; Pospisil V; Zavadil J; Trneny M; Klener P; Stopka T
Blood Cancer J; 2016 Sep; 6(9):e475. PubMed ID: 27662204
[No Abstract] [Full Text] [Related]
20. Chronic Lymphocytic Leukaemia: Census of Patients Treated in Italian Haematology Units.
Salvi G; Innocenti I; Autore F; Laurenti L
Mediterr J Hematol Infect Dis; 2015; 7(1):e2015056. PubMed ID: 26543525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
